Korea South
NGeneBio Co., Ltd. is a prominent company in the field of molecular diagnostics (MDx) and companion diagnostics (CDx), specializing in the development of next generation sequencing (NGS)-based in vitro diagnostics (IVD) panels and clinical analysis software (SW). Launched in October 2015 and headquartered in Seoul, South Korea, NGeneBio is a joint venture between Genecurix and Korea Telecom.
The company's flagship product, the NGS-based hereditary breast/ovarian cancer panel (BRCAaccuTestTM) with clinical analysis SW (NGeneAnalysisTM), was introduced in 2016. NGeneBio has ambitious plans for expansion, including the launch of a BRCA NGS panel for PARP inhibitor CDx test and solid tumor/hematologic cancer NGS panels, accompanied by a clinical data analysis SW platform.
NGeneBio's mission is to provide clinically validated NGS-based IVD/CDx products/services with a focus on innovative bioinformatics and SW development capacity for the global market. The company secured a significant KRW12.00B Series B investment on 20 November 2018 from a consortium of investors including DSC Investment, Korea Venture Investment Corp, IMM Investment, and UTC Investment.
NGeneBio's pioneering work in the biotechnology sector, combined with its strategic partnerships and recent substantial investment, positions the company as a key player in the development of cutting-edge diagnostics and analysis solutions.
